​

Lucid Diagnostics Stock (NASDAQ:LUCD)

ForecastRevenueOwnershipFinancialsChartTranscripts
Lucid Diagnostics by TradingView

Previous Close

$0.90

52W Range

$0.63 - $1.50

50D Avg

$0.87

200D Avg

$0.85

Market Cap

$53.40M

Avg Vol (3M)

$446.64K

Beta

1.42

Div Yield

-

LUCD Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

70

IPO Date

Oct 14, 2021

Website

LUCD Performance

LUCD Financial Summary

Dec 23Dec 22Dec 21
Revenue$2.43M$377.00K$500.00K
Operating Income$-48.48M$-56.17M$-27.42M
Net Income$-52.67M$-56.17M$-28.74M
EBITDA$-45.98M$-54.23M$-27.41M
Basic EPS$-1.26$-1.55$-1.54
Diluted EPS$-1.26$-1.55$-1.54

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 13, 24 | 2:44 PM
Q2 24Aug 12, 24 | 1:32 PM
Q1 24May 13, 24 | 12:00 AM

Peer Comparison

TickerCompany
LUNGPulmonx Corporation
KIDSOrthoPediatrics Corp.
FNAParagon 28, Inc.
CLPTClearPoint Neuro, Inc.
NARIInari Medical, Inc.
NPCENeuroPace, Inc.
LIVNLivaNova PLC
XAIRBeyond Air, Inc.
IRMDIRadimed Corporation
SRDXSurmodics, Inc.
ITGRInteger Holdings Corporation
OFIXOrthofix Medical Inc.
CVRXCVRx, Inc.